Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local Therapies + Erlotinib in Oligometastatic EGFR+ NSCLC
NCT02450591Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Feasibility as Measured by at Least Five Patients Will Need to Complete Local Therapy at 2 years. Started May 2015; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02450591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02450591.